Associated Banc-Corp Decreased Its 3M Co (MMM) Stake; Lombard Odier Asset Management Usa Has Decreased Its Cymabay Therapeutics (CBAY) Holding

3M Company (NYSE:MMM) Logo

Associated Banc-Corp decreased 3M Co (MMM) stake by 2.47% reported in 2018Q2 SEC filing. Associated Banc-Corp sold 1,709 shares as 3M Co (MMM)’s stock rose 0.89%. The Associated Banc-Corp holds 67,435 shares with $13.27 million value, down from 69,144 last quarter. 3M Co now has $117.74B valuation. The stock decreased 3.14% or $6.56 during the last trading session, reaching $202.2. About 2.70 million shares traded or 3.72% up from the average. 3M Company (NYSE:MMM) has declined 1.40% since December 5, 2017 and is downtrending. It has underperformed by 17.02% the S&P500. Some Historical MMM News: 09/03/2018 – FDA: 3M Company – Health Care Business- ACE (TM) BRAND, DELUXE ANKLE BRACE, 207736, UPC 0 51131 20387 7; 24/04/2018 – 3M CO MMM.N SEES FY 2018 ADJUSTED SHR $10.20 TO $10.55 EXCLUDING ITEMS; 07/03/2018 – GRAPHIC-GE value could slip to lowest among large U.S. industrials; 11/04/2018 – The Sky’s the Limit in 3M Disruptive Design Challenge; 22/03/2018 – Universal Laser Systems Expands Its Materials Database with 3M Materials; 09/03/2018 – UK ECONOMY ESTIMATED TO HAVE GROWN BY 0.3 PCT 3M/3M IN FEB – NIESR; 17/04/2018 – 3M Design and Architectural Markets Business Inspire Visitors at Milan Design Week 2018; 22/03/2018 – Global Low Temperature Sterilization Market Analysis & Outlook 2018-2022 Featuring Johnson & Johnson, 3M, Getinge and Steris – ResearchAndMarkets.com; 04/04/2018 – C3 IOT ANNOUNCED MULTI-YEAR AGREEMENT WITH 3M TO PROVIDE C3 IOT Al AND IOT SOFTWARE PLATFORM TO SUPPORT 3M’S DIGITAL TRANSFORMATION; 08/05/2018 – 3M Board Declares Quarterly Dividend

Lombard Odier Asset Management Usa Corp decreased Cymabay Therapeutics Inc (CBAY) stake by 6.19% reported in 2018Q2 SEC filing. Lombard Odier Asset Management Usa Corp sold 25,000 shares as Cymabay Therapeutics Inc (CBAY)’s stock declined 0.61%. The Lombard Odier Asset Management Usa Corp holds 379,000 shares with $5.09M value, down from 404,000 last quarter. Cymabay Therapeutics Inc now has $520.09 million valuation. The stock decreased 5.20% or $0.48 during the last trading session, reaching $8.75. About 348,766 shares traded. CymaBay Therapeutics, Inc. (NASDAQ:CBAY) has risen 94.06% since December 5, 2017 and is uptrending. It has outperformed by 78.44% the S&P500. Some Historical CBAY News: 11/04/2018 – CBAY:SELADELPAR SHOWED ANTI-INFLAMMATORY ACTIVITY THRU 26 WEEKS; 07/05/2018 – Cymabay Therapeutics at Deutsche Bank Conference Tomorrow; 11/04/2018 – CYMABAY THERAPEUTICS INC – SELADELPAR MAINTAINS POTENT ANTI-CHOLESTATIC AND ANTI-INFLAMMATORY ACTIVITY; 15/03/2018 CymaBay Therapeutics 4Q Loss/Shr 11c; 18/05/2018 – HistoIndex and CymaBay Therapeutics Team up to Advance NASH Drug Development; 08/05/2018 – CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic Steatohepatitis; 19/03/2018 – Cymabay Therapeutics at Investor Day Hosted By H.C. Wainwright; 08/05/2018 – CYMABAY THERAPEUTICS INC – QTRLY SHR LOSS $0.32; 11/04/2018 – CymaBay Announces Positive New 12-Week and 26-Week Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primar; 18/05/2018 – Histolndex and CymaBay Therapeutics Team up to Advance NASH Drug Development

Among 7 analysts covering 3M (NYSE:MMM), 3 have Buy rating, 1 Sell and 3 Hold. Therefore 43% are positive. 3M had 13 analyst reports since July 12, 2018 according to SRatingsIntel. The rating was maintained by Deutsche Bank on Friday, November 16 with “Hold”. Credit Suisse maintained 3M Company (NYSE:MMM) rating on Wednesday, October 24. Credit Suisse has “Outperform” rating and $222 target. The rating was maintained by Barclays Capital with “Underweight” on Wednesday, October 24. On Thursday, August 30 the stock rating was maintained by UBS with “Neutral”. The firm earned “Underweight” rating on Monday, November 19 by Barclays Capital. The firm earned “Hold” rating on Friday, September 28 by Deutsche Bank. The company was maintained on Thursday, July 12 by Deutsche Bank. The stock of 3M Company (NYSE:MMM) has “Neutral” rating given on Wednesday, October 24 by UBS. Barclays Capital maintained it with “Underweight” rating and $201 target in Wednesday, July 25 report. The rating was maintained by Argus Research on Wednesday, October 24 with “Buy”.

Associated Banc-Corp increased Comcast Corp New (NASDAQ:CMCSA) stake by 28,484 shares to 605,324 valued at $19.86 million in 2018Q2. It also upped Bank Amer Corp (NYSE:BAC) stake by 27,611 shares and now owns 328,171 shares. Associated Banc Corp (NYSE:ASB) was raised too.

Investors sentiment increased to 0.97 in 2018 Q2. Its up 0.20, from 0.77 in 2018Q1. It increased, as 73 investors sold MMM shares while 549 reduced holdings. 111 funds opened positions while 490 raised stakes. 374.25 million shares or 0.96% less from 377.88 million shares in 2018Q1 were reported. Cls Invests Lc holds 0.01% or 2,148 shares in its portfolio. Hall Laurie J Trustee invested in 4.02% or 35,584 shares. Manchester Cap Management Limited Liability has 11,175 shares for 0.33% of their portfolio. Sir Lp has invested 1.32% in 3M Company (NYSE:MMM). Focused Wealth Management reported 1,732 shares. Synovus Fincl Corporation accumulated 40,184 shares or 0.13% of the stock. Wafra Inc holds 0.62% in 3M Company (NYSE:MMM) or 83,498 shares. Pinnacle Wealth Mgmt Advisory Gru Limited Company holds 8,395 shares or 0.89% of its portfolio. Pennsylvania Trust Com invested in 1.21% or 137,092 shares. Anderson Hoagland And invested in 7,075 shares or 0.78% of the stock. Clifford Swan Investment Counsel Ltd Limited Liability Company invested in 0.76% or 69,398 shares. Pinnacle Limited Company owns 18,988 shares. Moreover, One National Association has 0.39% invested in 3M Company (NYSE:MMM) for 27,306 shares. New York State Teachers Retirement Systems owns 945,732 shares. Cypress Asset Tx reported 12,424 shares.

More notable recent 3M Company (NYSE:MMM) news were published by: Seekingalpha.com which released: “3M CEO sets five-year financial targets – Seeking Alpha” on November 15, 2018, also Seekingalpha.com with their article: “3M: Optimistic, But A Few Caveats – Seeking Alpha” published on November 11, 2018, Seekingalpha.com published: “As Expected, Evolution, Not Revolution, From 3M – Seeking Alpha” on November 20, 2018. More interesting news about 3M Company (NYSE:MMM) were released by: Seekingalpha.com and their article: “3M Company (MMM) CEO Michael Roman Presents at Credit Suisse 6th Annual Industrials Conference (Transcript) – Seeking Alpha” published on November 28, 2018 as well as Fool.com‘s news article titled: “Will 3M’s New 5-Year Financial Plan Help the Stock Recover? – The Motley Fool” with publication date: December 01, 2018.

Analysts await 3M Company (NYSE:MMM) to report earnings on January, 24. They expect $2.28 EPS, up 8.57% or $0.18 from last year’s $2.1 per share. MMM’s profit will be $1.33 billion for 22.17 P/E if the $2.28 EPS becomes a reality. After $2.58 actual EPS reported by 3M Company for the previous quarter, Wall Street now forecasts -11.63% negative EPS growth.

Since September 10, 2018, it had 1 buying transaction, and 1 sale for $90,252 activity. $274,752 worth of stock was sold by Hammes Eric D. on Monday, September 10. $184,500 worth of stock was bought by PAGE GREGORY R on Friday, October 26.

More notable recent CymaBay Therapeutics, Inc. (NASDAQ:CBAY) news were published by: Globenewswire.com which released: “CymaBay Therapeutics to Participate in Upcoming Investor Conferences – GlobeNewswire” on November 20, 2018, also Nasdaq.com with their article: “Report: Exploring Fundamental Drivers Behind ForeScout Technologies, GNC, Dova Pharmaceuticals, CymaBay Therapeutics, Adesto Technologies, and Clearside Biomedical — New Horizons, Emerging Trends, and Upcoming Developments – Nasdaq” published on November 27, 2018, Globenewswire.com published: “CymaBay Reports Third Quarter 2018 Financial Results and Provides Corporate Update – GlobeNewswire” on November 06, 2018. More interesting news about CymaBay Therapeutics, Inc. (NASDAQ:CBAY) were released by: Nasdaq.com and their article: “CymaBay Therapeutics Presents Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC at The Liver Meeting® 2018 – Nasdaq” published on November 13, 2018 as well as Seekingalpha.com‘s news article titled: “Fortress Biotech among healthcare gainers; Novelion Therapeutics leads losers – Seeking Alpha” with publication date: November 13, 2018.

Lombard Odier Asset Management Usa Corp increased Xl Group Ltd (Put) stake by 11,300 shares to 51,300 valued at $2.87M in 2018Q2. It also upped Ship Finance International L (NYSE:SFL) stake by 50,100 shares and now owns 165,000 shares. Transocean Ltd (Put) (NYSE:RIG) was raised too.

3M Company (NYSE:MMM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.